Post-hoc analyses of Surrogate Markers of Non-Alcoholic Fatty Liver Disease (NAFLD)  and Liver Fibrosis in Patients with Type  Diabetes in a Digitally-Supported Continuous  Eduardo Vilar-Gomez, Shaminie J
;    Mailing address:  Rotary Cir, Suite , Indianapolis, IN    DATA SHARING: Data sets and statistical code used for the current study are available from  CCI, continuous care intervention; UC, usual care; NAFLD, non-alcoholic fatty liver disease;;  N-LFS, non-alcoholic liver fatty score; NFS, non-alcoholic fatty liver disease fibrosis score;  CLD, chronic liver disease; HCC, hepatocellular carcinoma; TD, type  diabetes; NASH, non- alcoholic steatohepatitis; BMI, body mass index; LCHF, low-carbohydrate high-fat; ALT,  weight loss; EOT, end-of-treatment; HDL, high density lipoprotein; RCT, randomized  controlled trial; LCD, low-carbohydrate diet; KD, ketogenic diet; HFD, high-fat diet
;    Objective:  One-year of comprehensive continuous care intervention (CCI) through nutritional  ketosis improves HbAc, body weight and liver enzymes among type  diabetes (TD) patients
;     This study highlights the beneficial effect of the CCI on NAFLD in high risk patients   This study also identifies positive associations between glycemic improvements and   The assessment of resolution of steatosis and fibrosis is limited by the sensitivity and   The patients were restricted in their carbohydrate intake and monitored for their  nutritional ketosis state, but dietary energy, macronutrient and micronutrient intakes were  not certified by peer review) is the author/funder
Among all patients, ancillary aims included  assessing if changes in weight and HbAc were associated with ALT and metabolic parameter  improvements, and potential relationships between changes in the ALT with other metabolic  The design and primary results of this study were previously published, and the current  results are based on a -year post-hoc analysis using the data collected from the same cohort in  that clinical study (Clinical trials
We also recruited and followed a cohort of UC patients with TD (n=)  who received a standard diabetes care treatment from their primary care physician or  Primary outcomes-NAFLD liver fat and liver fibrosis by non-invasive surrogate markers  NAFLD liver fat score (N-LFS) is a surrogate marker of fatty liver which includes the  presence of the metabolic syndrome, type  diabetes, fasting serum insulin, AST and the  AST/ALT ratio
The equations for calculating both scores are displayed in the supplementary   Results from other metabolic (HbAc, fasting glucose, fasting insulin, HOMA-IR,  triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol), liver (ALT, AST, ALP),  kidney (creatinine, eGFR), beta-hydroxybutryrate (BHB) and high sensitivity C-reactive protein  (hsCRP) parameters were previously published in the full CCI and UC cohort []
The on-site and virtual CCI patients were grouped together for analyses since no  significant differences were observed in biochemical markers between these two modes of  not certified by peer review) is the author/funder
For this set of analyses, multiple imputation (  imputations) was used to replace missing values from baseline and  year with a set of plausible  The second study aim was to explore relationships between () changes in weight loss  and HbAc categories and its associations with ALT and metabolic parameters improvements  and () changes in ALT and metabolic variables
;    Haenszel  tests to assess changes in the proportions of patients meeting clinical cut-offs (for  ALT, N-LFS and NFS normalization) within different weight and HbAc categories
  At  year, beneficial changes observed in the metabolic parameters of the full CCI  cohort[,] were also reported in the subset of patients with abnormal baseline ALT, including  not certified by peer review) is the author/funder
 Abbreviations: SE, standard error; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase;   HbAc, Glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rates;   CKD-EPI, chronic kidney disease-epidemiological collaboration equation; BHB, beta-hydroxybutyrate; NAFLD, nonalcoholic fatty liver disease;   a Subgroup analysis of participants with abnormal ALT at baseline
Among patients with TD, a moderate-carbohydrate  modified Mediterranean diet (% carbohydrates, % high monounsaturated fat) showed  greater ALT reductions than two other higher carbohydrate hypocaloric diets including the   Our results also demonstrated that non-invasive risk scores for fatty liver and fibrosis  were improved in patients who underwent CCI as compared to the UC control, and greater  reductions were observed in patients with the largest reductions in body weight ( %)
;    In conclusion, one year of a digitally-supported continuous care intervention including  individualized nutritional ketosis led to significant improvement in non-invasive markers of liver  fat and fibrosis together with sustained weight loss in overweight and obese type  diabetes  patients